Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences to work with university on "next generation" rape case kit

Florida International University and pressure cycling technology specialist Pressure BioSciences are developing a rape case kit that could clear the backlog on unprocessed cases
Pressure BioSciences to work with university on "next generation" rape case kit
Future commercialization of this novel, PCT-based method could potentially provide significant new business channels for PBI

Medtech firm Pressure BioSciences (OTCQB:PBIO) has sealed a collaborative research and development agreement with Florida International University (FIU).

The collaboration will combine the advantages of Pressure BioSciences’ (PBI's) pressure cycling technology (PCT) platform with the forensic experience and expertise of FIU, with the aim of reducing the rape kit testing backlog.

The two will work on the development of a rape kit test method based on the PCT platform, and hope to have a commercial product available within the next 18 months.

There is an enormous pent-up demand for such a product, with the backlog of untested rape kits in the US estimated at 400,000, and with an estimated 180,000 sexual assault cases reported annually, that number looks in little danger of going down as things stand.

The collection of biological samples on cotton swabs for forensic analysis has been standard practice for many years, but the recovery of high quality DNA from these swabs is very difficult, as the biological sample is often trapped in the swab's cotton fibers, resulting in a loss of precious evidence, PBI said.

The problem is particularly prevalent with rape kits, where the male suspect's DNA must be isolated from a complex mixture of male and female cells.

A recent publication by doctors McCord and Nori of FIU discussed a novel, PCT-based technique that showed decreased processing times and higher yields while using inexpensive reagents on a semi-automated platform.

“We are excited by this opportunity to expand the range of applications of PCT in forensic analysis, specifically to assist in the development of a rapid and direct alternative to current methods for the analysis of rape kits,” said Dr Bruce McCord of FIU.

“In this project, we will further improve and validate this new PCT-based method. We believe this method will be able to isolate male and female DNA, even in situations where trace amounts of male DNA remain. We also believe that this PCT-based method could be significantly faster and provide improved sample recovery when compared to current methods. These advantages should be well received by the forensic community," he added.

Richard Schumacher, president and chief executive officer of PBI, said: "The progress that Dr McCord and his team have recently made is very impressive: we believe they are now very close to the development of a ‘next generation’ PCT-based rape kit. 

“Because of this progress, and because their future success requires immediate financial and scientific support, FIU and PBI have agreed to enter into a 16-month collaboration. During this time, PBI will offer FIU scientific and engineering support, to help optimize and streamline the method. PBI will also grant $70,000 to FIU over the term of the collaboration to help cover the costs of personnel and lab supplies," he added.

"We believe this new method offers an important potential breakthrough in the recovery of high quality DNA from cotton swabs. We further believe that combining the capabilities, knowledge, and our shared interest in an effective outcome, we can more effectively move this innovative method down the path to successful commercialization," Schumacher concluded.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
numerous pills
March 24 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use